Simulation Plus to provide 50 GastroPlus software licenses to FDA

Simulations Plus, Inc, a provider of consulting services and software for pharmaceutical discovery and development, announced on September 17 that the U.S. Food and Drug Administration’s (FDA) Office of New Drug Products, Division of Biopharmaceutics has placed an order for 50 additional licenses to the Company’s GastroPlus software.

gastroplusSimulations Plus says that this order brings to 70 the total number of GastroPlus licenses in use at the FDA. The licenses are spread across various divisions, including the Office of Generic Drugs, Center for Veterinary Medicine, Office of Clinical Pharmacology, and the National Center for Toxicological Research.

“Development of PBPK simulations for long-acting injectable microspheres.”
John DiBella, vice president of marketing and sales for Simulations Plus, said: “We are very pleased with the expanding use of our software products by regulatory agencies. The FDA Office of Generic Drugs has purchased 10 licenses to GastroPlus for many years. One of the reasons for an order for additional licenses of this magnitude is to meet the needs of other FDA divisions to review an increasing number of regulatory submissions referencing GastroPlus modeling. Scientists at the FDA want to understand how they can encourage more use of the software program to address questions related to complex drug product behaviors.”

Simulations Plus also recently announced that the company has been awarded a second cooperative agreement from the FDA for $200,000 per year for up to three years. This new project is for “Development of PBPK simulations for long-acting injectable microspheres.”

Dr. Ted Grasela, president of Simulations Plus and its wholly owned subsidiary, Cognigen, said: “We are pleased to build on our relationships with the FDA and industry-wide recognition of the value of our software products. The FDA continues to explore new ways of utilizing modeling and simulation in all aspects of research and development, and this is reflected in the need for additional licenses.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.